A half tablet swallowed every night, reflexively, with the reassuring belief of “being careful.” It is a gesture millions of French people have been repeating for months, sometimes years, convinced that by dividing the dose they also divide the risks. Yet, for pharmacists and health authorities, the assessment is more nuanced, even frankly worrying. Because dependence on benzodiazepines is not measured solely in milligrams. It also hides in regularity, in habit, in this small evening ritual that settles in without us really noticing. So, does this half-sleeping pill truly protect against the dreaded insomnia? The figures and official recommendations provide answers worth knowing.
Why the half-dose doesn’t really change the game
The idea seems common sense: cut the tablet in two, reduce the dose, therefore reduce the risk. But this reasoning, as logical as it seems on the surface, overlooks a crucial element. The problem with hypnotic benzodiazepines isn’t only the amount absorbed; it’s also how long and how regularly they are taken. A half-pill swallowed every night for months, or even years, with the justification of “it’s almost nothing,” becomes a habit that endures. And it is precisely this chronicity that concerns health professionals. The body and brain adapt, and dependence can develop even at doses considered therapeutic. In other words, the lower dose provides psychological comfort, but it does not necessarily protect against the habituation mechanism that quietly takes hold.
What the numbers reveal about benzodiazepine use
Data from the French Health Insurance, drawn from the Sniiram database for the period July 2023 to June 2024, paints a fairly clear picture. In France, 2.7 million adults use hypnotic benzodiazepines, with an annual reimbursed expenditure approaching 20 million euros. A figure that is awe-inspiring, especially since these medications are intended for short-term use. Another notable element: 75% of the patients are aged 50 or older, and more than half of the expenditure is concentrated among people aged 65 and up. But perhaps the most telling figure remains this: more than two-thirds of adult patients on hypnotic benzodiazepines exceed the maximum allowed duration of four weeks. In other words, the exception has effectively become the norm in practice.
The real risks of daily intake, even at a low dose
This is probably the point many pharmacists observe at the counter, though they don’t always take the time to explain it in detail to patients—either for lack of time or for fear of unnecessarily alarming them. For hypnotic benzodiazepines and related medicines, dependence can appear even at therapeutic doses, i.e., without any abuse or deliberate dose overstepping. The possible adverse effects are not trivial: confusion, memory problems, reduced alertness, daytime sleepiness. In older individuals, these vigilance problems often translate into an increased risk of falls, a complication that can carry far heavier consequences than a restless night. And when stopping the treatment is considered, withdrawal or rebound insomnia is not uncommon, sometimes returning with greater intensity than before. A cycle that can seem endless if nothing is anticipated.
What health authorities recommend before any prescription
In light of these findings, the HAS (Haute Autorité de Santé) issued clear recommendations in July 2024. The message is unequivocal: benzodiazepines should be prescribed as a second-choice option only, after non-pharmacological measures have failed. The aim is also to curb long-term prescriptions and, above all, to anticipate stopping the treatment from the outset rather than waiting for the situation to settle in. The indication remains strict: a short-term treatment for severe sleep disturbances, i.e., at least four nights per week with daytime impairment. These medicines are not indicated for chronic insomnia, those lasting more than three months. Before any prescription, the clinician must assess the nature of the insomnia, the patient’s physiological state, comorbidities, and the risks of drug interactions. Certain situations even completely contraindicate this treatment, notably severe respiratory failure, sleep apnea syndrome, severe liver failure, or myasthenia gravis. The Health Insurance also recalls a simple but too often forgotten rule: the maximum prescription duration is four weeks, with gradual tapering included.
Alternatives to prioritize in the face of sleep disturbances
Even before considering a drug treatment, official recommendations emphasize a step often neglected: non-pharmacological measures. As first-line therapy, sleep hygiene rules remain the foundation: regular bedtimes, reducing screen time in the evening, and an environment conducive to rest. Cognitive-behavioral therapies, commonly known by the acronym CBT, should also be favored before any drug prescription. However, it would be simplistic to think that all sleep treatments are the same or follow identical rules; each situation merits individualized assessment.
How to spot and escape an established dependency
Identifying misuse is not always straightforward, neither for the patient nor for healthcare providers, as the habit of a half-pill can seem harmless over time. Some signs deserve attention:
- a daily intake that extends well beyond the initial four weeks
- a feeling of daytime sleepiness or reduced vigilance
- episodes of confusion or small memory lapses
- signs of psychological or physical dependence
In the face of these signals, the solution is never to stop abruptly and alone. Such a decision can trigger withdrawal or a particularly uncomfortable rebound effect. The right approach is to reassess the situation with a healthcare professional, a doctor or a pharmacist, to consider a gradual and supported reduction. There are screening tools for misuse that help clinicians identify these situations and offer tailored support, rather than simply renewing a prescription out of habit.
Ultimately, this evening half-pill is never entirely harmless, even when it becomes a reassuring anchor. It is wiser to discuss it openly with your doctor or pharmacist than to let a night-after-night habit take hold whose boundaries are poorly understood.
Sources: The role of benzodiazepines in adult sleep disorders (ameli.fr) | Treatment of insomnia (ameli.fr)
Article prepared with the help of AI · Our method